Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

易普利姆玛 无容量 医学 危险系数 内科学 肿瘤科 黑色素瘤 安慰剂 转移性黑色素瘤 免疫疗法 癌症 置信区间 癌症研究 病理 替代医学
作者
Jedd D. Wolchok,Vanna Chiarion-Sileni,Rene Gonzalez,Piotr Rutkowski,Jean-Jacques Grob,C. Lance Cowey,Christopher D. Lao,John Wagstaff,Dirk Schadendorf,Pier Francesco Ferrucci,Michael Smylie,Reinhard Dummer,Andrew F. Hill,David W. Hogg,John B. A. G. Haanen,Matteo S. Carlino,Oliver Bechter,Michele Maio,Ivan Marquez-Rodas,Massimo Guidoboni,Grant A. McArthur,Céleste Lebbé,Paolo A. Ascierto,Georgina V. Long,Jonathan Cebon,Jeffrey A. Sosman,Michael A. Postow,Margaret K. Callahan,Dana Walker,Linda Rollin,Rafia Bhore,F. Stephen Hodi,James Larkin
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:377 (14): 1345-1356 被引量:2947
标识
DOI:10.1056/nejmoa1709684
摘要

Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial.We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group.At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group.Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小北发布了新的文献求助200
1秒前
xx驳回了囧囧的应助
1秒前
bonnie发布了新的文献求助10
2秒前
海绵球完成签到,获得积分10
4秒前
JIANHUAN发布了新的文献求助10
4秒前
5秒前
小蘑菇的应助被fat采纳,获得10
5秒前
9秒前
机灵曼荷完成签到,获得积分10
9秒前
rxw完成签到,获得积分10
10秒前
笨笨西装完成签到,获得积分10
10秒前
10秒前
青橙发布了新的文献求助10
10秒前
科研通AI65的应助被虚幻的从蓉采纳,获得10
11秒前
11秒前
11秒前
爱笑海亦发布了新的文献求助10
11秒前
ding的应助被hhhh采纳,获得10
11秒前
lele发布了新的文献求助10
11秒前
芊芊完成签到,获得积分10
12秒前
科研通AI6.4的应助被如懿采纳,获得10
12秒前
茉莉冰提发布了新的文献求助10
12秒前
李倇仪完成签到 ,获得积分10
12秒前
蓝天发布了新的文献求助10
12秒前
风吹麦浪发布了新的文献求助10
13秒前
13秒前
14秒前
慕青的应助被9465426采纳,获得30
15秒前
共享精神的应助被黎明采纳,获得10
15秒前
yang完成签到 ,获得积分20
16秒前
16秒前
17秒前
18秒前
18秒前
18秒前
今后的应助被回望采纳,获得10
18秒前
浪里个浪发布了新的文献求助10
19秒前
帅气一凤完成签到,获得积分10
20秒前
思源的应助被AK采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067